HOWL (Werewolf Therapeutics, Inc. Common Stock) Stock Analysis - News
Werewolf Therapeutics, Inc. Common Stock (HOWL) is a publicly traded Healthcare sector company. As of May 21, 2026, HOWL trades at $0.44 with a market cap of $24.07M and a P/E ratio of -0.34. HOWL moved +3.43% today. Year to date, HOWL is -32.03%; over the trailing twelve months it is -61.58%. Its 52-week range spans $0.40 to $4.18. Rallies surfaces HOWL's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
What changed in HOWL news today?
Werewolf Therapeutics Narrows Q4 Loss to $8.4M, Engages Piper Sandler: Werewolf Therapeutics ended 2025 with $57.1 million in cash, projecting funding into Q4 2026, and narrowed its Q4 net loss to $8.4 million from $20.4 million year-over-year, yielding a full-year net loss of $60.8 million versus $70.5 million in 2024. The company cut R&D expenses to $6.9 million and engaged Piper Sandler to explore strategic alternatives.
EVNIN LUKE sold 85.89K (~$36.93K) on May 20, 2026.
EVNIN LUKE sold 62.97K (~$28.34K) on May 19, 2026.
EVNIN LUKE sold 22.18K (~$11.09K) on May 18, 2026.
HOWL Analyst Consensus
HOWL analyst coverage data. Average price target: $0.00.
Common questions about HOWL
What changed in HOWL news today?
Werewolf Therapeutics Narrows Q4 Loss to $8.4M, Engages Piper Sandler: Werewolf Therapeutics ended 2025 with $57.1 million in cash, projecting funding into Q4 2026, and narrowed its Q4 net loss to $8.4 million from $20.4 million year-over-year, yielding a full-year net loss of $60.8 million versus $70.5 million in 2024. The company cut R&D expenses to $6.9 million and engaged Piper Sandler to explore strategic alternatives.
Does Rallies summarize HOWL news?
Yes. Rallies summarizes HOWL news with ticker-specific context, catalysts, source links, and AI-generated market summaries when news is available.
Is HOWL research on Rallies investment advice?
No. Rallies provides research, data, and educational context for HOWL. It does not provide personalized investment advice.
